Cart
sales@molnova.com
TG-101348
CAS No. 936091-26-8
TG-101348( Fedratinib | SAR 302503 | TG101348 | TG 101348 )
Catalog No. M16699 CAS No. 936091-26-8
TG-101348 (Fedratinib, SAR302503) is a potent, selective JAK2 inhibitor with IC50 of 3 nM for both wt JAK2 and JAK2 V617F.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 49 | In Stock |
|
| 5MG | 43 | In Stock |
|
| 10MG | 60 | In Stock |
|
| 50MG | 107 | In Stock |
|
| 100MG | 126 | In Stock |
|
| 200MG | 212 | In Stock |
|
| 500MG | 462 | In Stock |
|
| 1G | 612 | In Stock |
|
Biological Information
-
Product NameTG-101348
-
NoteResearch use only, not for human use.
-
Brief DescriptionTG-101348 (Fedratinib, SAR302503) is a potent, selective JAK2 inhibitor with IC50 of 3 nM for both wt JAK2 and JAK2 V617F.
-
DescriptionTG-101348 (Fedratinib, SAR302503) is a potent, selective JAK2 inhibitor with IC50 of 3 nM for both wt JAK2 and JAK2 V617F; also inhibits FLT3 (IC50=15 nM) and RET (IC50=48 nM) kinases, weakly inhibits JAK3 (IC50=168 nM), >35-fold selectivity over JAK1/3 and Tyk2; shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation; also potently inhibits BRD4 with Kd of 168 nM.Bone Cancer Phase 3 Clinical.
-
In Vitro——
-
In VivoAnimal Model:C57Bl/6 mice induced by the JAK2V617F mutation Dosage:60 mg/kg, 120 mg/kg Administration:Oral gavage; twice daily; for 42 days Result:Showed a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis.
-
SynonymsFedratinib | SAR 302503 | TG101348 | TG 101348
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorFLT3|JAK2|JAK2(V617F)|RET
-
Research AreaCancer
-
IndicationBone Cancer
Chemical Information
-
CAS Number936091-26-8
-
Formula Weight524.6782
-
Molecular FormulaC27H36N6O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 42 mg/mL
-
SMILESO=S(C1=CC=CC(NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O
-
Chemical NameBenzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pardanani A, et al. Leukemia. 2007 Aug;21(8):1658-68.
2. Ciceri P, et al. Nat Chem Biol. 2014 Apr;10(4):305-12.
3. Wernig G, et al. Cancer Cell. 2008 Apr;13(4):311-20.
4. Geron I, et al. Cancer Cell. 2008 Apr;13(4):321-30.
molnova catalog
related products
-
JAK-IN-3
JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.
-
Axltide
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).Peptide sequence (KKSRGDYMTMQIG) is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).
-
JAK2-IN-7
JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.
